Gen Precision expands the GTK-OSI1 for production-line inspection of FAUs with up to 80 channels and custom structures, delivering 3σ ≤ 0.1 μm repeatability.

TAOYUAN, Sept. 14, 2026 /PRNewswire/ — Gen Precision is expanding its inspection capabilities for co-packaged optics (CPO) applications as manufacturers seek higher-precision, more flexible inspection of fiber array units (FAUs) and related components. The company now supports FAU configurations with up to 80 channels and custom components with specialized structures, while helping customers deploy these inspection capabilities on production lines to accelerate product qualification and production ramp-up for next-generation optical communications products.

“Passive optical components have traditionally followed standard 1×M or M×N array formats, but AI infrastructure is driving higher-density and increasingly customized designs,” said Jacky Chang, Executive Vice President and Special Assistant to the Chairman at Gen Precision. “Inspection must evolve with these products. By adapting our inspection methods to different designs and validating them with actual customer samples, we help customers advance new optical products with greater confidence.”

Gen Precision has completed inspection and validation projects for multiple customers, including non-standard custom designs, and has shipped its first batch of automated inspection systems.

GTK-OSI1 Expands FAU Inspection to Specialized Structures

Gen Precision has expanded the capability of the GTK-OSI1 Automated Passive Optical Component Inspection Machine beyond standard FAU-related component inspection, adding support for custom components and production-line deployment. By combining AOI-based precision measurement, automation control, AI-powered visual recognition, and software development capabilities, Gen Precision can adapt the system to different component designs.

The GTK-OSI1 delivers measurement repeatability of 3σ ≤ 0.1 μm for Fiber Arrays (FA), V-Grooves, and MT/MMC ferrules. Based on customer sample validation, measurement scripts and fixtures can be customized for deployment in automated production-line workflows. Once specifications are confirmed, Gen Precision can complete system customization and delivery within 6 to 8 months.

From Component Inspection to CPO Performance Validation

Gen Precision will further extend its optical communications automation capabilities into post-packaging performance testing. In collaboration with Lintes Technology, Gen Precision will develop a CPO test system to validate the performance of packaged products integrating an Optical Engine and FAU. Drawing on its expertise in precision machining, metrology, and automation, the initiative will extend Gen Precision’s capabilities beyond component-level dimensional inspection to include post-packaging performance validation, supporting customers across a broader range of optical product development stages.

About Gen Precision

Established in 1992 and headquartered in Taoyuan, Taiwan, Gen Precision offers fully integrated in-house capabilities in nanoscale precision mold manufacturing, automation system development, and injection molding.

Backed by an ISO 9001–certified quality management system, we deliver key components and integrated automation solutions for semiconductor, optical communications, healthcare, and electronics industries. With long-term global partnerships and customized support, we help customers optimize operations, improve yield, and create lasting value at scale.

Learn more at gentk.com or follow us on LinkedIn.

Demand for multi-venue competition grows in South Korea to prevent ‘blind trading’ during U.S. overnight session

CHICAGO and SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ — Bruce Markets, which operates the overnight U.S. equities trading venue Bruce ATS, today announced that Meritz Securities, a leading Korean investment bank and broker-dealer, has connected to Bruce ATS’ market data feed for overnight U.S. equities. The integration provides Meritz Securities with greater visibility into quote and trade activity on Bruce ATS throughout the 8:00 p.m. – 4:00 a.m. ET overnight U.S. session, broadening customers’ view of U.S. equity prices during the Korean business day.

The milestone comes as South Korean traders fight ‘blind trading’ and reassert their role as one of the most important sources of overnight U.S. equity demand:

• Korean brokerages resumed daytime access to U.S. stocks in November 2025 following a 15-month suspension, with stronger safeguards and a multi-venue framework.
• Bruce Markets analysis found that total overnight notional activity nearly doubled between the November reopening and March 2026.
• Since November 2025, several venue-specific symbol restrictions have reinforced the importance of multi-venue competition. Multiple trading venues help Korean retail traders access pricing data and avoid ‘blind trading’ – a need underscored in September when one venue halted trading in five symbols that collectively averaged 15+ million daily shares in August.

“Healthy markets are built on competition, transparency and choice. Bruce’s share of reported overnight volume nearly doubled in Q2 because market participants increasingly recognize the value of having more than one credible source of liquidity and data,” said Jason Wallach, CEO of Bruce Markets. “Meritz Securities’ connection brings a more complete view of the overnight session in U.S. equities to one of its most important investor bases. That visibility is essential if Korean firms are going to prevent blind trading and deliver the high-quality experience customers deserve.”

Meritz Securities’ connection to Bruce ATS market data reflects accelerating growth in overnight U.S. equities. Across the three leading overnight ATSs, Q2 trading reached 11.14 billion shares and $391.2 billion in notional value – increases of 34% and 59% from Q1, respectively – according to the Bruce Q2 Overnight Market Review.

Bruce ATS accelerated significantly in Q2, with executed volume up 144% to 1.16 billion shares and executed notional up 105% to $49.03 billion. The momentum has continued into September, with Bruce’s share of reported overnight notional climbing from 14.13% to a record 20.77%, and its share of monthly overnight volume rising from 11.66% to 16.4%.

“Meritz Securities is pleased to expand Korean investors’ access to the U.S. overnight equity market through Bruce ATS,” Meritz Securities said in a statement. “This collaboration reflects our commitment to providing clients with broader market access and a stable, reliable trading experience across extended trading hours.”

As Korean demand for U.S. equities continues to expand, a competitive, multi-venue ecosystem ensures market resilience and gives brokers, traders and liquidity providers multiple pathways to see and reach liquidity across a wider range of market conditions.

About Bruce Markets
Bruce Markets operates Bruce ATS™, a U.S. equities alternative trading system enabling overnight trading from 8:00 PM to 4:00 AM ET. Underpinned by exchange-grade technology and market rules, led by industry veterans and backed by leading firms from across the trading ecosystem, Bruce provides a high-performance, resilient venue that bridges the U.S. after-hours and pre-market sessions. By providing a credible source of after-hours liquidity for brokers and investors and leading the evolution of always-available markets, Bruce brings needed competition to the ecosystem and is redefining after-hours trading worldwide. To learn more, visit www.brucemarkets.com.

About Meritz Securities
Meritz Securities Co., Ltd. is a South Korean financial services firm and member of Meritz Financial Group. The company provides securities brokerage, investment banking, sales and trading, and other financial services to retail, institutional and corporate clients. Meritz continues to expand its retail and global investing capabilities through technology-led platforms that bring together trading, information, analysis and investor communities. To learn more, visit home.imeritz.com.

Media Contacts
Forefront Communications for Bruce Markets
bruce@forefrontcomms.com 

Meritz Securities
prd@meritz.co.kr 

• Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).
• Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients.
• FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines®.
• Pixclara expands Telix’s industry-leading Precision Medicine business and reinforces the Company’s leadership in diagnostics and targeted radiopharmaceutical therapies (together, “theranostics”).

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or ¹⁸F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Pixclara is a radioactive diagnostic drug indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

PET imaging with floretyrosine F 18 (FET-PET) is recommended in international clinical practice guidelines for the imaging of gliomas, including NCCN Guidelines®^[1], but until now there has not been an FDA-approved product available in the U.S.

Gliomas are the most common form of central nervous system (CNS) cancer, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors^[2]. In the U.S., approximately 24,000 new glioma cases are diagnosed each year^[3], representing a significant unmet addressable need.

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, “FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients.”

Kelly Sitkin, President and CEO, American Brain Tumor Association, said, “The approval of Pixclara will advance glioma care by enabling more precise monitoring, complementing the role of MRI. We welcome the FDA’s decision, which provides a pathway to access this technology in the U.S. and helps address a critical unmet need in brain cancer diagnostics.”

Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, said, “Having an FDA-approved FET-PET product with high diagnostic accuracy will make a significant, positive difference to the management of patients with gliomas. This is a very positive step forward for brain cancer imaging and treatment planning.”

About Pixclara (floretyrosine F 18)

Pixclara® is an intravenous positron emission tomography (PET) imaging drug for the differentiation of recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older. It comprises a small molecule targeting compound labeled with a diagnostic radioisotope, fluorine-18. After administration into the bloodstream, Pixclara targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). Once bound, energy emissions from the radioisotope can be detected by a PET scanner. Pixclara (TLX101-Px) is also the subject of a Phase 3 registrational study for potential indication expansion for the diagnosis of brain metastases^[4].

Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. 

Telix’s commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma imaging. The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (¹³¹I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. TLX591-Tx, TLX101-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Package combines a one-night stay with collectible T-money cards designed with traditional mother-of-pearl and longevity motifs, plus vouchers across LOTTE affiliates

SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ — LOTTE HOTELS & RESORTS, South Korea’s largest hotel group, today announced the launch of the LOTTE HOTEL REWARDS Exclusive Travel Pass, a package for international visitors that pairs a one-night stay with two limited-edition LOTTE HOTEL T-money transit cards. The pass is available at ten properties in Seoul, Busan and Jeju, with bookings open through December 29, 2026, for stays through December 31, 2026.

A Transit Card Designed as a Keepsake

The T-money card is a prepaid transit card used across South Korea for subways, buses and taxis, as well as at convenience stores and affiliated merchants. The limited-edition version created for this package incorporates two elements of Korean decorative tradition: jagae, the mother-of-pearl inlay long used in Korean lacquerware, and sipjangsaeng, the ten symbols of longevity — including the crane, deer, pine and tortoise — that appear in Korean painting and craft as wishes for long life. The design also features the LOTTE World Tower, the tallest building in South Korea.

Each card is preloaded with KRW 3,000 (approximately USD 2), allowing guests to use it immediately upon arrival.

Benefits Across LOTTE Affiliates

The package includes voucher benefits across major LOTTE affiliates:

• Dining privileges at hotel bakeries and lounges
• Membership upgrades and shopping benefits at LOTTE DUTY FREE
• Admission discounts at LOTTE WORLD
• Shopping perks at LOTTE MART stores nationwide

Availability

The pass is available at ten LOTTE HOTELS & RESORTS properties: THE GRAND LOTTE SEOUL, LOTTE HOTEL WORLD, LOTTE HOTEL BUSAN, L7 BY LOTTE HOTELS (Myeongdong, Hongdae, Gangnam, Haeundae), and LOTTE CITY HOTELS (Myeongdong, Jeju, Guro).

The package is offered exclusively to international members of LOTTE HOTEL REWARDS. Membership is free, and reservations can be made immediately through the official LOTTE HOTELS & RESORTS website (www.lottehotel.com/global) or mobile app under the “Special Offers” page.

HONG KONG, Sept. 13, 2026 /PRNewswire/ — SUNMI Technology (06810.HK) announced on September 10, separate cooperation agreements with Türkiye-based fintech company TOKEN and Mongolia-based digital bank M bank at the 11th Belt and Road Summit in Hong Kong.

The agreements will bring together SUNMI’s commercial IoT and digital commerce capabilities with the partners’ local expertise, advancing collaboration across digital commerce, smart devices, payments, and digital financial services.

In Türkiye, SUNMI and TOKEN will explore digital commerce solutions for banks and offline merchants, combining SUNMI’s commercial IoT capabilities with TOKEN’s payment technology and local market expertise.

In Mongolia, SUNMI and M bank will combine commercial devices, digital technology and digital financial services to explore new digital solutions for small and medium-sized businesses.

“Hong Kong is a vital gateway connecting China with global markets,” said Sam, CMO of SUNMI. “Our collaboration with TOKEN and M bank brings SUNMI’s technology together with strong local partners. We look forward to working with more partners across Eurasia to make digitalization more accessible to businesses in every market.”

The agreements mark another step in SUNMI’s global ecosystem strategy. SUNMI will continue to work with local partners to connect smart devices, business software, payments and digital services, developing solutions that meet the needs of offline businesses in local markets.